Of interest, some cases from our series exhibited NPM1-mutated-reactive T-cell responses five years or later after the completion of anti-leukemic treatments, further suggesting that specific immune responses could have a central role in the long-term favorable clinical outcomes, at least in some NPM1-mutated AML patients [19]. This evidence concerns the gene NPM1 and acute myeloid leukemia.